BD 100m syringe expansion, page-4

Not for this instance anyway, it's all about the Insulin Syringes:

BD invests $100m in Nebraska manufacturing plant expansion

September 22, 2016 By Fink Densford Leave a Comment

Becton Dickinson & Co. (NYSE:BDX) said today it is investing $100 into expanding its Holdrege, Neb.-based facility to make extra room for insulin syringe manufacturing operations.
The investment will support new manufacturing equipment and tech to expand production for BD insulin syringes, the Franklin Lakes, N.J.-based company said. BD currently produces more than 2 billion insulin syringes per year.
“About 40 percent of people with diabetes who inject insulin use syringes as part of their diabetes management regimen. This investment will provide benefits to this diabetes population and underscores our commitment to supply high-quality, industry-leading insulin syringes to patients,” BD diabetes care worldwide prez Ken Miller said in a press release.
BD’s Holdrege facility is 350,00 square foot and was established originally in 1966. The facility houses more than 650 employees and manufactures 20 different products, BD said.
In August, Becton Dickinson marked 60 years of running a facility in Sandy, Utah, by pledging a $20 million upgrade to the facility, which makes IV catheters and valves, blood collection devices and surgical products.
BD said it bought the site dates back to Deseret Pharmaceutical, which opened in Murray, Utah, in 1956. BD bought the plant in in 1986 and grew it to 550,000 square feet and 1,200 employees.
BD said the Sandy plant was its 1st to use renewable energy sources for all of its power back in 2008. Four years later the site became “landfill-free” where waste is reduced, recycled or converted into energy, the company said.